Poster ID – **P0198**

LABORATOIRE A-DERMA

Tolerance and efficacy of a new emollient eyelid balm containing Rhealba oat and *Helichrysum g.* in eyelid eczema

K. Bouyer[1], A. Brocario[2], A. Philippe[1], V. Mengeaud[2], M.D. Thouvenin[1]

1. *R&D Department, Pierre Fabre Dermo-Cosmetics & Personal Care, Toulouse, France*
2. *Medical Department, Laboratoire Dermatologique A-DERMA, Pierre Fabre Dermo-Cosmetics & Personal Care, Lavaur, France*

Introduction & Objectives


Eyelid eczema, whether of atopic, allergic or irritant origin, is a frequent condition in dermatological practice and is particularly challenging to manage due to the thinness and high reactivity of periocular skin. In this sensitive area, therapeutic options are limited and long-term use of topical treatments is often constrained by tolerability or cosmetic concerns. There is therefore a need for well-tolerated, effective emollient formulations specifically designed for the eye contour, to help restore the skin barrier and relieve pruritus and discomfort.

A new **emollient balm** specifically dedicated to the eyelid area, containing **Rhealba oat** and ***Helichrysum g.***, has been developed. The objective of this study was to evaluate the **dermatological and ophthalmological tolerability and efficacy** of this product in adults with **dry eyelid eczema**.

Materials & Methods

STUDY DESIGN

Multicenter open-label study



MAIN INCLUSION CRITERIA

Dry eyelid eczema with:

- **Xerosis**: ≥ 2 (mild) (0-4 scale)
- **Erythema**: = 2 *(except for Ph.V)* (0-4 scale)
- **Discomfort sensation**: ≥ 3 (NRS 0-10)
- **Pruritus**: intensity (over the last 24hrs) ≥ 3 (NRS 0-10)

EVALUATIONS

- PHYSICAL AND FUNCTIONAL SIGNS
- DERMATOLOGICAL & OPHTHALMOLOGICAL TOLERABILITY
- PRURITUS (NRS)
- DISCOMFORT SENSATIONS (NRS)
- COSMETIC ACCEPTABILITY
- GLOBAL EFFICACY*

** Evaluated only at D22*

POPULATION

34
adults presenting dry eyelid eczema
Atopic (n=22)
Allergic (n=7)
Irritant (n=5)


19-63 years
mean age 38 years

76.5% / 23.5%
women / men

All phototypes
Phototype I: 3%
Phototype II: 32%
Phototype III: 32%
Phototype IV: 18%
Phototype V: 15%

Results


Erythema



SCORING: FROM 0 (NO SIGN) TO 4 (SEVERE) by the Investigator
D1T0: Before product application
D1Timm: Immediately after product application

Mean ± SEM / ** p<0.01; *** p<0.001 vs baseline (D1T0)

Xerosis



SCORING: FROM 0 (NO SIGN) TO 4 (SEVERE) by the Investigator
D1T0: Before product application
D1Timm: Immediately after product application

Mean ± SEM / *** p<0.001 vs baseline (D1T0)

Conclusions


- ✓ These results demonstrate the benefit of this new emollient eyelid balm, which combines very good dermatological and ophthalmological tolerance with a rapid and sustained improvement of the symptoms and clinical signs of dry eyelid eczema.
- ✓ Its very good cosmetic acceptability on the periocular area supports its use as a valuable supportive care option in the management of dry eyelid eczema.

Tolerability

Tolerability rated as ‘very good’ by the dermatologist and the ophthalmologist after **21 days** of twice daily use

Pruritus Intensity


Average intensity over the last 24hrs



NUMERIC RATING SCALE (NRS): 0 (no itch) to 10 (worst imaginable itch)
D1T0: Before product application

Mean ± SEM
*** p<0.001 vs baseline

Discomfort sensations



NUMERIC RATING SCALE (NRS): 0 (no discomfort) TO 10 (worst imaginable discomfort)
D1T0: Before product application
D1Timm: Immediately after product application

Mean ± SEM
*** p<0.001 vs baseline

Illustrative pictures



Photo credits: *Pierre Fabre Dermo-Cosmétique*

Female subject, 57 years old Mean case based on clinical scoring xerosis, erythema/ Standard lighting

Cosmetic acceptability

- **GLOBAL APPRECIATION: 8.3 / 10 AT DAY 22**
- **97% OF THE SUBJECTS JUDGED THEIR SKIN AS COMFORTABLE AND SOOTHED AT DAY 22**

Global efficacy

After 21 days of use

Global efficacy of the product judged as ‘effective’ to ‘very effective’:

- by 97% of the subjects
- for 100% of subjects by the investigator

Presented at the European Academy of Dermatology and Venereology Annual Congress, 30 September to 3 October 2026, Vienna, Austria